Skip to main content
Top
Published in: BMC Infectious Diseases 1/2021

Open Access 01-12-2021 | Research article

Factors associated with delayed presentation to healthcare facilities for Lassa fever cases, Nigeria 2019: a retrospective cohort study

Authors: Nastassya L. Chandra, Hikaru Bolt, Chioma Dan-Nwafor, Oladipupo Ipadeola, Elsie Ilori, Geoffrey Namara, Adebola T. Olayinka, Winifred Ukponu, Akanimo Iniobong, Michael Amedu, Adejoke Akano, Kachikwulu O. Akabike, Uwaifiokun Okhuarobo, Stephen Fagbemi, Emeka Sampson, Sophie Newitt, Neville Q. Verlander, Daniel G. Bausch, Olivier le Polain de Waroux, Chikwe Ihekweazu

Published in: BMC Infectious Diseases | Issue 1/2021

Login to get access

Abstract

Background

Large outbreaks of Lassa fever (LF) occur annually in Nigeria. The case fatality rate among hospitalised cases is ~ 20%. The antiviral drug ribavirin along with supportive care and rehydration are the recommended treatments but must be administered early (within 6 days of symptom onset) for optimal results. We aimed to identify factors associated with late presentation of LF cases to a healthcare facility to inform interventions.

Methods

We undertook a retrospective cohort study of all laboratory confirmed LF cases reported in Nigeria from December 2018 to April 2019. We performed descriptive epidemiology and a univariate Cox proportional-hazards regression analysis to investigate the effect of clinical (symptom severity), epidemiological (age, sex, education, occupation, residential State) and exposure (travel, attendance at funeral, exposure to rodents or confirmed case) factors on time to presentation.

Results

Of 389 cases, median presentation time was 6 days (IQR 4–10 days), with 53% attending within 6 days. There were no differences in presentation times by sex but differences were noted by age-group; 60+ year-olds had the longest delays while 13–17 year-olds had the shortest. By sex and age, there were differences seen among the younger ages, with 0–4-year-old females presenting earlier than males (4 days and 73% vs. 10 days and 30%). For 5–12 and 13–17 year-olds, males presented sooner than females (males: 5 days, 65% and 3 days, 85% vs. females: 6 days, 50% and 5 days, 61%, respectively). Presentation times differed across occupations 4.5–9 days and 20–60%, transporters (people who drive informal public transport vehicles) had the longest delays. Other data were limited (41–95% missing). However, the Cox regression showed no factors were statistically associated with longer presentation time.

Conclusions

Whilst we observed important differences in presentation delays across factors, our sample size was insufficient to show any statistically significant differences that might exist. However, almost half of cases presented after 6 days of onset, highlighting the need for more accurate and complete surveillance data to determine if there is a systemic or specific cause for delays, so to inform, monitor and evaluate public health strategies and improve outcomes.
Literature
4.
go back to reference Dan-Nwafor CC, Furuse Y, Ilori EA, Ipadeola O, Akabike KO, Ahumibe A, et al. Measures to control protracted large Lassa fever outbreak in Nigeria, 1 January to 28 April 2019. Eurosurveillance. 2019;24(20):1900272. Dan-Nwafor CC, Furuse Y, Ilori EA, Ipadeola O, Akabike KO, Ahumibe A, et al. Measures to control protracted large Lassa fever outbreak in Nigeria, 1 January to 28 April 2019. Eurosurveillance. 2019;24(20):1900272.
5.
go back to reference Nigeria Centre for Disease Control. 2019 Lassa Fever Outbreak Situation Report: Epi Week 21. 2019. Nigeria Centre for Disease Control. 2019 Lassa Fever Outbreak Situation Report: Epi Week 21. 2019.
6.
go back to reference Nigeria Centre for Disease Control. 2018 Lassa Fever Outbreak Situation Report: Epi Week 21. 2018. Nigeria Centre for Disease Control. 2018 Lassa Fever Outbreak Situation Report: Epi Week 21. 2018.
7.
go back to reference Nigeria Centre for Disease Control. 2017 Lassa Fever Outbreak Situation Report: Epi Week 51. 2017. Nigeria Centre for Disease Control. 2017 Lassa Fever Outbreak Situation Report: Epi Week 51. 2017.
8.
go back to reference Eberhardt KA, Mischlinger J, Jordan S, Groger M, Günther S, Ramharter M. Ribavirin for the treatment of Lassa fever: a systematic review and meta-analysis. Int J Infect Dis. 2019;87:15–20.CrossRef Eberhardt KA, Mischlinger J, Jordan S, Groger M, Günther S, Ramharter M. Ribavirin for the treatment of Lassa fever: a systematic review and meta-analysis. Int J Infect Dis. 2019;87:15–20.CrossRef
9.
go back to reference Richmond JK, Baglole D. Lassa fever: epidemiology, clinical features, and social consequences. Bmj. 2003;327(7426):1271–5.CrossRef Richmond JK, Baglole D. Lassa fever: epidemiology, clinical features, and social consequences. Bmj. 2003;327(7426):1271–5.CrossRef
10.
go back to reference McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM, et al. Lassa fever. N Engl J Med. 1986;314(1):20–6.CrossRef McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM, et al. Lassa fever. N Engl J Med. 1986;314(1):20–6.CrossRef
11.
go back to reference Needham DM, Foster SD, Tomlinson G, Godfrey-Faussett P. Socio-economic, gender and health services factors affecting diagnostic delay for tuberculosis patients in urban Zambia. Trop Med Int Health. 2001;6(4):256–9. Needham DM, Foster SD, Tomlinson G, Godfrey-Faussett P. Socio-economic, gender and health services factors affecting diagnostic delay for tuberculosis patients in urban Zambia. Trop Med Int Health. 2001;6(4):256–9.
12.
go back to reference Hasker E, Lumbala C, Mbo F, Mpanya A, Kande V, Lutumba P, et al. Health care-seeking behaviour and diagnostic delays for Human African Trypanosomiasis in the Democratic Republic of the Congo. Trop Med Int Health. 2011;16(7):869–74. Hasker E, Lumbala C, Mbo F, Mpanya A, Kande V, Lutumba P, et al. Health care-seeking behaviour and diagnostic delays for Human African Trypanosomiasis in the Democratic Republic of the Congo. Trop Med Int Health. 2011;16(7):869–74.
13.
go back to reference Ukwaja KN, Alobu I, Nweke CO, Onyenwe EC. Healthcare-seeking behavior, treatment delays and its determinants among pulmonary tuberculosis patients in rural Nigeria: a cross-sectional study. BMC Health Serv Res. 2013;13(1):25.CrossRef Ukwaja KN, Alobu I, Nweke CO, Onyenwe EC. Healthcare-seeking behavior, treatment delays and its determinants among pulmonary tuberculosis patients in rural Nigeria: a cross-sectional study. BMC Health Serv Res. 2013;13(1):25.CrossRef
14.
go back to reference Thaddeus S, Maine D. Too far to walk: maternal mortality in context. Soc Sci Med. 1994;38(8):1091–110.CrossRef Thaddeus S, Maine D. Too far to walk: maternal mortality in context. Soc Sci Med. 1994;38(8):1091–110.CrossRef
15.
go back to reference Calvello EJ, Skog AP, Tenner AG, Wallis LA. Applying the lessons of maternal mortality reduction to global emergency health. Bull World Health Organ. 2015;93:417–23.CrossRef Calvello EJ, Skog AP, Tenner AG, Wallis LA. Applying the lessons of maternal mortality reduction to global emergency health. Bull World Health Organ. 2015;93:417–23.CrossRef
16.
go back to reference National Malaria Elimination Programme, National Population Commission, National Bureau of Statistics and ICF International. Nigeria malaria indicatory survey 2015. Abuja, and Rockville: NMEP, NPopC, and ICF International.; 2016. National Malaria Elimination Programme, National Population Commission, National Bureau of Statistics and ICF International. Nigeria malaria indicatory survey 2015. Abuja, and Rockville: NMEP, NPopC, and ICF International.; 2016.
19.
go back to reference Avis WR. Urban expansion in Nigeria. Brighton: Institute of Development Studies; 2019. Avis WR. Urban expansion in Nigeria. Brighton: Institute of Development Studies; 2019.
20.
go back to reference Ofem BI. A review of the criteria for defining urban areas in Nigeria. J Hum Ecol. 2012;37(3):167–71.CrossRef Ofem BI. A review of the criteria for defining urban areas in Nigeria. J Hum Ecol. 2012;37(3):167–71.CrossRef
22.
go back to reference Hulland E, Wiens K, Shirude S, Morgan J, Bertozzi-Villa A, Farag T, et al. Travel time to health facilities in areas of outbreak potential: maps for guiding local preparedness and response. BMC Med. 2019;17(1):1–16.CrossRef Hulland E, Wiens K, Shirude S, Morgan J, Bertozzi-Villa A, Farag T, et al. Travel time to health facilities in areas of outbreak potential: maps for guiding local preparedness and response. BMC Med. 2019;17(1):1–16.CrossRef
23.
go back to reference Theocharopoulos G, Danis K, Greig J, Hoffmann A, De Valk H, Jimissa A, et al. Ebola management centre proximity associated with reduced delays of healthcare of Ebola Virus Disease (EVD) patients, Tonkolili, Sierra Leone, 2014–15. PloS one. 2017;12(5):e0176692. Theocharopoulos G, Danis K, Greig J, Hoffmann A, De Valk H, Jimissa A, et al. Ebola management centre proximity associated with reduced delays of healthcare of Ebola Virus Disease (EVD) patients, Tonkolili, Sierra Leone, 2014–15. PloS one. 2017;12(5):e0176692.
24.
go back to reference Sinai I, Anyanti J, Khan M, Daroda R, Oguntunde O. Demand for women’s health services in northern Nigeria: a review of the literature. Afr J Reprod Health. 2017;21(2):96–108.CrossRef Sinai I, Anyanti J, Khan M, Daroda R, Oguntunde O. Demand for women’s health services in northern Nigeria: a review of the literature. Afr J Reprod Health. 2017;21(2):96–108.CrossRef
25.
go back to reference Silenou BC, Tom-Aba D, Adeoye O, Arinze CC, Oyiri F, Suleman AK, et al. Use of Surveillance Outbreak Response Management and Analysis System for Human Monkeypox Outbreak, Nigeria, 2017-2019. Emerg Infect Dis. 2020;26(2):345. Silenou BC, Tom-Aba D, Adeoye O, Arinze CC, Oyiri F, Suleman AK, et al. Use of Surveillance Outbreak Response Management and Analysis System for Human Monkeypox Outbreak, Nigeria, 2017-2019. Emerg Infect Dis. 2020;26(2):345.
26.
go back to reference McQuilkin PA, Udhayashankar K, Niescierenko M, Maranda L. Health-care access during the Ebola virus epidemic in Liberia. Am J Trop Med Hyg. 2017;97(3):931–6.CrossRef McQuilkin PA, Udhayashankar K, Niescierenko M, Maranda L. Health-care access during the Ebola virus epidemic in Liberia. Am J Trop Med Hyg. 2017;97(3):931–6.CrossRef
27.
go back to reference Adewole DA, Akanbi SA, Osungbade KO, Bello S. Expanding health insurance scheme in the informal sector in Nigeria: awareness as a potential demand-side tool. Pan Afr Med J. 2017;27:11092. Adewole DA, Akanbi SA, Osungbade KO, Bello S. Expanding health insurance scheme in the informal sector in Nigeria: awareness as a potential demand-side tool. Pan Afr Med J. 2017;27:11092.
Metadata
Title
Factors associated with delayed presentation to healthcare facilities for Lassa fever cases, Nigeria 2019: a retrospective cohort study
Authors
Nastassya L. Chandra
Hikaru Bolt
Chioma Dan-Nwafor
Oladipupo Ipadeola
Elsie Ilori
Geoffrey Namara
Adebola T. Olayinka
Winifred Ukponu
Akanimo Iniobong
Michael Amedu
Adejoke Akano
Kachikwulu O. Akabike
Uwaifiokun Okhuarobo
Stephen Fagbemi
Emeka Sampson
Sophie Newitt
Neville Q. Verlander
Daniel G. Bausch
Olivier le Polain de Waroux
Chikwe Ihekweazu
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2021
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-021-05822-4

Other articles of this Issue 1/2021

BMC Infectious Diseases 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.